Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Adagene Inc.

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene to Participate in Investor Conferences in September
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene to Present at Investor Conferences in June
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene to Present at Investor and Scientific Conferences in September
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Announces Updates to its Board of Directors
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Appoints Cuong Do to Board of Directors and Audit Committee
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in November
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback